Research map: Real-World Analysis of the Association Between Systemic Inflammation, Cardiovascular Events, and Economic Burden Among Patients with Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease

Back to the article

Papers in this map

  1. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies · Erik B von Elm · 2008 · 17695 citations · Cited by this paper
  2. Impella Versus VA-ECMO for Patients with Cardiogenic Shock: Preliminary Cost-Effectiveness Analysis in the Italian Context · 2025 · Related
  3. Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data · Hude Quan · 2005 · 10881 citations · Cited by this paper
  4. Treatment Patterns and Healthcare Resource Utilization Among Patients with Obstructive Hypertrophic Cardiomyopathy in Japan: A Claims Database Study · 2025 · Related
  5. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease · Paul M. Ridker · 2017 · 9543 citations · Cited by this paper
  6. A Summary of Cardiometabolic Disorders in the Maghreb: Insights from the 2025 Saclay Cardiometabolic Summit · 2026 · Related
  7. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein · Paul M. Ridker · 2008 · 6726 citations · Cited by this paper
  8. Macitentan in Pulmonary Arterial Hypertension Due to Congenital Heart Disease (CHD-PAH): Real-World Evidence from the OPUS/OrPHeUS Studies · 2024 · Related
  9. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines · Donna K. Arnett · 2019 · 4607 citations · Cited by this paper
  10. Current and Future Treatment Landscape of Transthyretin Amyloid Cardiomyopathy · 2025 · Related
  11. New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race · Lesley A. Inker · 2021 · 4530 citations · Cited by this paper
  12. Safety and Efficacy of Tafamidis in Chinese Patients with Transthyretin Amyloid Cardiomyopathy · 2025 · Related
  13. 2024 ESC Guidelines for the management of chronic coronary syndromes · Christiaan J. Vrints · 2024 · 2786 citations · Cited by this paper
  14. Cardiogenic Shock Centers and Protocols for Acute Cardiovascular Care: Bridging the Gap Between Spoke and Hub Sites · 2026 · Related
  15. C-Reactive Protein Levels and Outcomes after Statin Therapy · Paul M. Ridker · 2005 · 2309 citations · Cited by this paper
  16. Resistant Blood Pressure: New Frontiers in Interventional Hypertension Therapy · 2025 · Related
  17. Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events · Paul M. Ridker · 2001 · 1564 citations · Cited by this paper
  18. Patient Experience of Heart Disease with Elevated Lipoprotein(a): Views from a Patient, His Physician, and a Patient Association · 2025 · Related
  19. High-Sensitivity C-Reactive Protein · Paul M. Ridker · 2001 · 1410 citations · Cited by this paper
  20. Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels · Paul M. Ridker · 1998 · 1395 citations · Cited by this paper
  21. 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association · Seth Shay Martin · 2025 · 1044 citations · Cited by this paper
  22. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial · Paul M. Ridker · 2017 · 925 citations · Cited by this paper
  23. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial · Paul M. Ridker · 2021 · 736 citations · Cited by this paper
  24. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials · Paul M. Ridker · 2023 · 674 citations · Cited by this paper
  25. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias · François Mach · 2025 · 601 citations · Cited by this paper
  26. Inflammation and cardiovascular disease: From mechanisms to therapeutics · Abdulhamied Alfaddagh · 2020 · 476 citations · Cited by this paper
  27. Targeting cardiovascular inflammation: next steps in clinical translation · Patrick R. Lawler · 2020 · 450 citations · Cited by this paper
  28. A Test in Context · Paul M. Ridker · 2016 · 422 citations · Cited by this paper
  29. Colchicine in Acute Myocardial Infarction · Sanjit S. Jolly · 2024 · 322 citations · Cited by this paper
  30. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease · Paul M. Ridker · 2018 · 297 citations · Cited by this paper
  31. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia · Roger Scott Blumenthal · 2026 · 232 citations · Cited by this paper
  32. hsCRP Level and the Risk of Death or Recurrent Cardiovascular Events in Patients With Myocardial Infarction: a Healthcare‐Based Study · Juan Jesús Carrero · 2019 · 164 citations · Cited by this paper
  33. Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement · George A. Mensah · 2025 · 164 citations · Cited by this paper
  34. Interleukin‐6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID‐TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52) Trial · Christina L. Fanola · 2017 · 162 citations · Cited by this paper
  35. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance · Paul M. Ridker · 2023 · 146 citations · Cited by this paper
  36. Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease · Philip C. Robinson · 2021 · 132 citations · Cited by this paper
  37. Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy · Paul M. Ridker · 2022 · 117 citations · Cited by this paper
  38. Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease · Faizan Mazhar · 2024 · 83 citations · Cited by this paper
  39. Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement · Stefano Romeo · 2025 · 73 citations · Cited by this paper

Source: OpenAlex (CC0)